Introduction
Insulin resistance syndrome has been suggested as a major metabolic cause of atherosclerosis (1). The early events in the development of atherosclerosis may originate in endothelial dysfunction (2), which commonly occurs in patients with insulin resistant states, such as type 2 diabetes (3-6) and obesity (7). There is also a positive correlation between endothelial synthesis of nitric oxide and insulin sensitivity (8). Such findings suggest a possible pathophysiological link between insulin resistance, endothelial dysfunction and the development of early atherosclerosis. Troglitazone, which has the thiazolidinedione type structure, is a oral antidiabetic agent that ameliorates insulin sensitivity (9-11) and reduces hyperinsulinemia in patients with insulin resistance.
Therefore, troglitazone treatment may improve endothelial dysfunction if this is caused by insulin resistance. Flow-mediated dilatation(FMD) induced by reactive hyperemia is endothelium dependent (12-14) and can be assessed by high-resolution ultrasonography in the superficial arteries (15, 16) .
The present study analyzed the effects of troglitazone on endothelial function in individuals with insulin resistance by high-resolution ultrasonography. et al. To minimize the operator valiability this study was done with one operator who skilled at this procedure.
Methods

Laboratory tests
Fasting blood samples were taken at baseline and after 4 weeks.
Serum insulin level was measured by the double antibody technique (Dainabot, Tokyo, Japan). Plasma glucose concentrations were determined by the glucose oxidase method (Kainos, Tokyo, Japan). Glycosylated hemoglobin (HbA1c) was measured by high performance liquid chromatography with a normal range of 4.3-5.8% (TOHSOH, Tokyo, Japan). Serum total cholesterol, triglycerides and HDL cholesterol levels were measured using standard enzymatic methods (Kainos, Tokyo, Japan) and LDL cholesterol values were calculated using Friedewald's formula.
Peak particle diameter (PPD) of LDL was determined by gradient-gel electrophoresis according to Krauss and Burk with some modifications.
In brief, electrophoresis was performed on 2.5% to 16% gradient polyacrylamide gel (Biocraft, Tokyo, Japan). The gels were prerun in 90 mM Tris, 80 mM boric acid, and 2.5 mM EDTA, pH 8.3 at 150 V for 20 minutes. The samples (20 ,u L) were applied (40% sucrose, 1% bromophenol blue) to each lane on the gel. Electrophoresis was performed at 150 V for 18 hours at 4°C. The gels were stained with 0.04% Oil Red 0 in 60% ethanol for 24 hours, and fixed with 50% methanol plus 7% acetic acid containing Coomassie Brilliant Blue. After destaining with 25% ethanol plus 9% acetic acid, the gels were scanned using a densitometric image analyzer. The calibration curve was determined from high molecular-weight standards (thyroglobulin (17.0 nm) and apoferritin (12.2 nm)) and known diameter sample (25.7 nm). The estimated diameter for the major peak in each scan was termed the PPD.
The lipid peroxide levels in plasma were determined by measuring thiobarbituric acid reactive substances (TBARS) using a lipid-peroxide test kit (Wako Junyaku Co., Osaka Japan). This result was expressed as the malondialdehyde equivalent (nmol/ml).
Statistical analysis
Values are given as mean ±SD. The area under the curve (AUC) for insulin and glucose was calculated using the trapezoidal rule. Single variable comparisons for baseline and troglitazone treatment results used the paired t test. Comparison of groups used the unpaired t test. Linear regression analysis was used to compare two continuous variables.
All probability values for the statistical significance are two-tailed.
Results
All the subjects completed this study. Troglitazone was well-tolerated by all subjects, without serious sideeffects including elevation in serum transaminases (data not shown). Table 1 shows baseline characteristics and changes in metabolic variables.
The insulin resistant subjects were significantly older than normal subjects, and the estimated body mass index (BMI) was slightly larger but no subjects were obese.
Weight and blood pressures did not change during the study. Fasting glucose and insulin levels and responses to oral glucose load did not change in normal subjects.
In contrast both fasting glucose and insulin levels, and the response to oral glucose load were significantly reduced (p < 0.05) after treatment with troglitazone for 4 weeks in the insulin resistant subjects.
No significant changes occurred in total cholesterol, triglyceride or LDL cholesterol levels in control and insulin resistant subjects. However, HDL-cholesterol level was significantly increased after treatment with troglitazone in insulin resistant subjects. Table 2 shows the baseline and changes of the PPD and plasma TBARS levels caused by treatment with troglitazone for 4 weeks. No significant changes were observed in normal subjects.
However, PPD was significantly increased (p <0.01) and plasma TBARS was significantly reduced (p <0.05) in the insulin resistant subjects.
FMD of the brachial artery after reactive hyperemia was significantly impaired in the insulin resistant subjects compared to normal subjects at the baseline (Fig. 1) . A significant negative correlation was observed between the FMD and AUC insulin of response to glucose load at the baseline (r = -0.64, p <0.05) (Fig. 2) . No significant changes in NTG induced dilatation occurred in either group of subjects (Fig. 3) , but FMD was significantly increased by troglitazone for 4 weeks in the insulin resistant subjects (Fig. 3) .
Discussion
The present study demonstrated that the FMD of the brachial artery was impaired in insulin resistant subjects, and that troglitazone improved both the blunted vascular response and the insulin response.
The blunted response to reactive hyperemia in subjects We need further studies to clarify these findings.
The present study appears to contrast to a recently published study by Tack et al. (18) that failed to demonstrate any beneficial effects of troglitazone on endothelial function in the obese subjects. They found that troglitazone treatment improved neither vascular response to Data are mean +SD. Fig. 2 . Correlation between flow mediated dilatation and area under the curve of insulin response after 75 g oral glucose load at baseline in all subjects.
Flow mediated dilatation is expressed as percentage diameter changes of the brachial artery induced by reactive hyperemia. acetylcholine, an endothelial dependent vasodilator, nor insulin induced vasodilatation, and concluded that troglitazone had no effects on endothelial function.
However, the obese subjects included in their study had normal responses to acetylcholine even at baseline.
Therefore, their findings agree with ours in that troglitazone does not affect the vascular response in healthy subjects with normal endothelial function.
In conclusion, insulin resistant subjects show blunted FMD of the brachial artery, and troglitazone improves this impaired vascular response.
This finding suggests that primary treatment of insulin resistance could prevent the development of atherosclerosis by improving the endothelial function.
Further prospective studies are urgently needed to determine whether troglitazone therapy results in a better clinical outcome in such patients.
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